Wearable Biosensors · Renal Health
QuinSense is developing a minimally invasive wearable biosensor that tracks potassium and phosphate in interstitial fluid — turning a monthly lab snapshot into a continuous picture that patients and care teams can act on.
Dual-analyte microneedle patch · Pre-clinical development
The Problem
Dialysis patients live on a saw-tooth. Potassium and phosphate climb through every interdialytic gap and fall during each session — yet the standard of care samples that trajectory roughly once a month. A single draw cannot show rebound, dietary swings, or whether a binder regimen is actually working, and the interval between sessions is where avoidable emergencies happen.
Our Technology
A single minimally invasive microneedle patch samples dermal interstitial fluid and reads two ions that matter most in end-stage renal disease. They are not interchangeable: potassium is the acute channel, where minutes-to-hours changes carry arrhythmia risk and where forecasting saves lives. Phosphate is the chronic channel, a whole-body mineral burden whose value lies in seeing the trend across days.
Hyperkalemia is a genuine, life-threatening event, and it peaks the day after the long interdialytic break. A reactive dwell engine plus a machine-learning quantile forecaster watches for sustained excursions and flags risk before it becomes an admission.
High phosphate drives vascular calcification and cardiovascular mortality, and controlling it costs patients 6–15 binder pills a day. We report the trend against each patient's own baseline, annotated with meals, binders and dialysis — the picture a monthly draw structurally cannot produce.
The Signal
Ten days of modelled interstitial phosphate for a stage-5 patient on a Monday/Wednesday/Friday schedule. Every session cuts the level sharply; every gap rebuilds it. Switch the binder adherence to watch the same patient drift toward the action ceiling — then switch to monthly lab only to see how much of that story a single draw returns.
Illustrative output from our multi-pool phosphate model — a simulated patient, not clinical data. Serum-equivalent values use a provisional ISF→serum conversion and are shown as context only. Thresholds follow KDOQI/KDIGO guidance and remain subject to nephrologist sign-off.
Electronic Pathway
A reagent-free potentiometric front end keeps the signal chain shared between both analytes and the power budget small enough for a disposable patch. Calibration, filtering and the risk engine run on-device — no cloud round-trip, and no patient data leaving the wearable unless the patient and care team asks for it.
Target analytes sampled dermally
Electrochemical transduction
Proprietary hardware
Calibration, filtering, risk engine
Flux-based modeling and ML forecasting
Display, alerts, longitudinal view
Roadmap
Our development plan front-loads the questions that carry the most risk. The paired ISF↔serum phosphate validation study sits in Phase 2 by design — it is the one conversion the entire phosphate claim rests on, and it converts our largest open risk into evidence.
Phase 01
Bench-validated dual-analyte sensing, calibration model and a working patch prototype.
Phase 02
The paired ISF/serum phosphate study in ESRD, plus dermal-ISF phosphate sensor bench work.
Phase 03
Clinical study execution and the regulatory pathway toward market authorization.
Phase 04
Deployment with dialysis clinics and nephrology practices, then platform expansion.
We are targeting an unserved gap: continuous monitoring for CKD and mineral-bone disorder through ionic-analyte sensing. The same sensing platform extends naturally to other settings where continuous ion measurement matters — ICU monitoring, oncology supportive care and neuromodulation among them. Positioned as a supplement that keeps patients in range between sessions and reduces hospitalizations, alongside dialysis rather than replacing it.
Interactive Demo
Our working demo runs the same models this site is built on: the multi-pool phosphate simulation, the potassium risk engine with its dwell-based alerting, and a clinician roster view with triage flags and longitudinal summaries. Choose a synthetic patient, scrub the timeline and watch the alerts fire. SMS integration coming soon.
A hosted build is being prepared — check back shortly or email us for a walkthrough.
Patient Experience
The typical American starts dialysis at 64, and most patients carry a sharp distaste for complex patient interfaces as well as the treatment-day fatigue. The QuinSense patient app is built for that reality: Simple as possible. One number, one plain-English sentence, one clear next step. The full clinical picture never disappears, it waits one tap away, for the caregivers and care teams who want it.
The headline is a sentence: “A little high. Take your binders with your next meal.” Never a raw figure the patient has to decode against a reference range.
The key reading renders at 64 px and action text at 18 px, with colour pairings chosen for WCAG-AA contrast — readable without needing one's glasses.
Every action is a full-width, 58-pixel button: forgiving of tremor, arthritis and post-session fatigue. No gestures, no long-presses, no hidden menus.
Patients land on the Simple view. The Full view: trend charts, potassium risk, the clinician dashboard — sits behind a single toggle for family and care teams.
Same build as the interactive demo — the mock-up here mirrors its Simple view, pixel for pixel.
Prototype — not a medical device. This shows trends to help manage phosphate; it does not diagnose or replace your care team or lab tests.
Scroll the screen — mirrors the live demo build
The Team
QuinSense brings together expertise in bioelectronics, mechanical engineering, software and machine learning, clinical science, and regulatory affairs — a renal-physiology and ML capability held by one team, united around a single mission.
Get In Touch
Whether you're a potential partner, clinician, investor or patient advocate — we'd love to hear from you.
admin@quinsense.comHouston, Texas · Seed Stage
QuinSense is a pre-clinical medical device company working to change how dialysis patients monitor and manage their kidney health. We are actively seeking strategic partnerships, clinical collaborators and mission-aligned investors to accelerate our development timeline — starting with the paired ISF/serum phosphate validation study and dermal-ISF sensor bench work.